Genmab A/S Files Form 6-K for April 2025
Ticker: GNMSF · Form: 6-K · Filed: Apr 7, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing
TL;DR
Genmab filed a 6-K on 4/7/25, incorporating into its S-8s. Standard reporting.
AI Summary
Genmab A/S filed a Form 6-K on April 7, 2025, to report information for the month of April 2025. This report is incorporated by reference into several of Genmab's S-8 registration statements, including File No. 333-284876.
Why It Matters
This filing serves as an update for investors and indicates ongoing reporting requirements are being met by Genmab A/S.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previous information into registration statements and does not introduce new material financial or operational news.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
- 333-284876 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What type of SEC filing is this for Genmab A/S?
This is a Form 6-K report.
What is the filing date of this Form 6-K?
The filing date is April 7, 2025.
What period does this report cover?
This report is for the month of April 2025.
Which registration statements does this 6-K filing get incorporated into?
This filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What is the principal executive office address for Genmab A/S?
The address is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 7, 2025 regarding GENMAB A/S (GNMSF).